Funzela Special Precautions

Serious adverse hepatic effects have been reported with fluconazole. Although these are rare, these should be considered when giving fluconazole therapy. If signs and symptoms of liver disease develops, treatment should be discontinued immediately; if abnormal liver function tests occur, the patient should be carefully monitored for the possibility of more severe liver injury.
Overgrowth of nonsusceptible strains of candida have been reported in some patients receiving fluconazole. When this occurs, patients may require an alternative anti-fungal therapy.
Anaphylaxis has occurred rarely in patients taking fluconazole.
Rare but serious exfoliative skin disorders such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported during treatment with fluconazole which rarely resulted in a fatal outcome in patients with serious underlying diseases (predominantly AIDS & malignancy). It is recommended that in patients with superficial fungal infection, fluconazole treatment be discontinued at the first sign of rash. Patients with serious underlying disease who develop rashes should be closely observed and fluconazole treatment should be discontinued when bullous lesions or erythema multiforme progresses.
Carcinogenesis, Mutagenesis, Impairment of Fertility: Evidence of mutagenicity was not seen when fluconazole was used in vitro.
There was no evidence of carcinogenicity in studies done in mice and rats receiving fluconazole dosages of 2.5 to 10 mg/kg daily for 24 months. However, onset of parturition is slightly delayed.
Use in Children: A different dosing regimen is recommended for infants less than 4 weeks (see Dosage & Administration).
Use in Elderly: Since elderly patients are more likely to have impaired renal function, dosage should be modified as necessary. However, dosage adjustments based on age alone is not necessary.